About Ulisse BioMed
Ulisse BioMed is a company based in Udine (Italy) founded in 2015 by Bruna Marini.. Ulisse BioMed has raised $17.59 million across 4 funding rounds from investors including European Union and Global Corporate Finance. Ulisse BioMed offers products and services including Sagitta, NanoHybrid, Hyris System™, and Real Time PCR Kits. Ulisse BioMed operates in a competitive market with competitors including Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others.
- Headquarter Udine, Italy
- Founders Bruna Marini
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ulisse Biomed S.P.A.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17.59 M (USD)
in 4 rounds
-
Latest Funding Round
$11.71 M (USD), Series B
Sep 11, 2025
-
Investors
European Union
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ulisse BioMed
Ulisse BioMed offers a comprehensive portfolio of products and services, including Sagitta, NanoHybrid, Hyris System™, and Real Time PCR Kits. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for advanced molecular diagnostics and testing.
Technology for customized molecular analysis solutions.
System enabling real-time data access for molecular testing.
Kits for specific and sensitive clinical laboratory analysis.
Funding Insights of Ulisse BioMed
Ulisse BioMed has successfully raised a total of $17.59M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $11.71 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $11.7M
-
First Round
First Round
(01 Jun 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Series B - Ulisse BioMed | Valuation |
investors |
|
| Sep, 2022 | Amount | Grant - Ulisse BioMed | Valuation |
investors |
|
| Jun, 2017 | Amount | Series A - Ulisse BioMed | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ulisse BioMed
Ulisse BioMed has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and Global Corporate Finance. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global Corporate Finance is focused on equity investments worldwide.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ulisse BioMed
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ulisse BioMed
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ulisse Biomed Comparisons
Competitors of Ulisse BioMed
Ulisse BioMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of diagnostic solutions for systemic infections
|
|
| domain | founded_year | HQ Location |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| domain | founded_year | HQ Location |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| domain | founded_year | HQ Location |
Diagnostic technologies for infectious, cancer, and neurological diseases are developed.
|
|
| domain | founded_year | HQ Location |
Miniaturized MRI platforms for clinical diagnostics are developed.
|
|
| domain | founded_year | HQ Location |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ulisse Biomed
Frequently Asked Questions about Ulisse BioMed
When was Ulisse BioMed founded?
Ulisse BioMed was founded in 2015.
Where is Ulisse BioMed located?
Ulisse BioMed is headquartered in Udine, Italy. It is registered at Udine, Friuli-venezia Giulia, Italy.
Is Ulisse BioMed a funded company?
Ulisse BioMed is a funded company, having raised a total of $17.59M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4.8M, raised on Jun 01, 2015.
What does Ulisse BioMed do?
Ulisse BioMed was founded in 2015 in Udine, Italy, within the biotechnology sector. Molecular diagnostic test kits are produced via the sagitta platform for detecting respiratory infections, HPV, and nucleic acid extraction. A drug monitoring platform employing NanoHybrid technology is utilized to identify antibodies and protein analytes from serum or whole blood. Products are being developed to track drug availability and efficacy in patients treated with biologics or biosimilars.
Who are the top competitors of Ulisse BioMed?
Ulisse BioMed's top competitors include Visby Medical, Inflammatix and MeMed.
What products or services does Ulisse BioMed offer?
Ulisse BioMed offers Sagitta, NanoHybrid, Hyris System™, and Real Time PCR Kits.
Who are Ulisse BioMed's investors?
Ulisse BioMed has 2 investors. Key investors include European Union, and Global Corporate Finance.